Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Cancer Gene Ther. 2010 May 7;17(8):559–570. doi: 10.1038/cgt.2010.11

Figure 6.

Figure 6

Time course of AAVrh.10 mediated expression of anti-HER2 antibody in vivo. On day 0, C57Bl/6 mice (n=5/group) received intravenous administration of 1011 genome copies AAVrh.10αHER2-myc or AAVrh.10LacZ. Naive mice were used as an additional control. Serum was collected at different time points. A. Anti-HER2 antibody levels assessed by myc-specific Western analysis under non-reducing conditions. Serum from AAVrh.10αHER2-myc mice was pooled. Purified anti-HER2-myc was used as positive control. B. Serum anti-HER2 antibody levels were measured by human HER2-specific ELISA. Purified anti-HER2 antibody served as standard. Data was obtained from n=5 mice per group and is plotted as mean ± standard error.